Five Prime Therapeutics (FPRX) Upgraded to “Buy” at BidaskClub

BidaskClub upgraded shares of Five Prime Therapeutics (NASDAQ:FPRX) from a hold rating to a buy rating in a research note published on Wednesday.

Other equities research analysts also recently issued research reports about the company. Zacks Investment Research downgraded Five Prime Therapeutics from a buy rating to a hold rating in a research report on Wednesday. Wedbush began coverage on Five Prime Therapeutics in a research report on Thursday, May 17th. They issued a neutral rating and a $17.00 target price on the stock. ValuEngine downgraded Five Prime Therapeutics from a sell rating to a strong sell rating in a research report on Wednesday, April 18th. Goldman Sachs Group began coverage on Five Prime Therapeutics in a research report on Thursday, May 10th. They issued a neutral rating and a $20.00 target price on the stock. Finally, Nomura reduced their target price on Five Prime Therapeutics from $94.00 to $25.00 and set a buy rating on the stock in a research report on Wednesday, February 28th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the company. Five Prime Therapeutics presently has a consensus rating of Hold and a consensus target price of $33.00.

NASDAQ FPRX opened at $16.79 on Wednesday. The firm has a market cap of $625.67 million, a price-to-earnings ratio of -3.12 and a beta of 3.41. Five Prime Therapeutics has a fifty-two week low of $15.66 and a fifty-two week high of $48.87.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.08). The company had revenue of $32.49 million for the quarter, compared to analyst estimates of $37.50 million. Five Prime Therapeutics had a negative return on equity of 44.36% and a negative net margin of 221.74%. equities analysts forecast that Five Prime Therapeutics will post -4.64 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in shares of Five Prime Therapeutics by 20.8% in the 1st quarter. BlackRock Inc. now owns 2,653,489 shares of the biotechnology company’s stock valued at $45,585,000 after buying an additional 457,380 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Five Prime Therapeutics by 15.5% in the 1st quarter. Victory Capital Management Inc. now owns 1,067,090 shares of the biotechnology company’s stock valued at $18,332,000 after buying an additional 142,900 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Five Prime Therapeutics by 6.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,041,750 shares of the biotechnology company’s stock valued at $17,897,000 after buying an additional 67,474 shares during the period. BB Biotech AG raised its holdings in shares of Five Prime Therapeutics by 18.1% in the 1st quarter. BB Biotech AG now owns 977,500 shares of the biotechnology company’s stock valued at $16,793,000 after buying an additional 150,000 shares during the period. Finally, Rock Springs Capital Management LP raised its holdings in shares of Five Prime Therapeutics by 37.8% in the 1st quarter. Rock Springs Capital Management LP now owns 585,500 shares of the biotechnology company’s stock valued at $10,059,000 after buying an additional 160,500 shares during the period. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply